On October 6, 2021 NextEra Energy, Inc. (NYSE: NEE) reported that it plans to report third-quarter 2021 financial results before the opening of the New York Stock Exchange on Wednesday, Oct. 20, 2021, in a news release to be posted on the company’s website at www.NextEraEnergy.com/FinancialResults (Press release, Nextera, OCT 6, 2021, View Source [SID1234590875]). The company will issue an advisory news release over PR Newswire the morning of Oct. 20, with a link to the financial results news release on the company’s website. As previously communicated, the company will make available its financial results only on its website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jim Robo, chairman and chief executive officer of NextEra Energy, Rebecca Kujawa, executive vice president, finance and chief financial officer of NextEra Energy, and other members of the company’s senior management team will discuss the company’s third-quarter 2021 financial results during an investor presentation to be webcast live, beginning at 9 a.m. ET on Oct. 20. Results for NextEra Energy Partners, LP (NYSE: NEP) also will be discussed during the same investor presentation.

The listen-only webcast will be available on NextEra Energy’s website by accessing the following link: www.NextEraEnergy.com/FinancialResults. The financial results news release and the slides accompanying the presentation may be downloaded at www.NextEraEnergy.com/FinancialResults, beginning at 7:30 a.m. ET on the day of the webcast. A replay will be available for 90 days by accessing the same link as listed above.

On October 6, 2021 Race Oncology ("Race") reported that it has been issued a new patent (US 11,135,201) from the United States Patent and Trademarks Office (USPTO) for its cancer drug, Zantrene (bisantrene dihydrochloride) (Press release, Race Oncology, OCT 6, 2021, View Source [SID1234591004]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This is Race’s fifth patent granted for Zantrene in the United States. "This latest US patent provides Race with additional protection around the use, formulation and compositions of Zantrene (and related chemical structures) that improve the therapeutic benefit of Zantrene", said Race’s CEO & Managing Director, Phillip Lynch.

The new patent builds on Race’s existing Zantrene patents granted in the USA in 2018 (US 9,993,460 and US 9,974,774), 2019 (US 10,500,192) and in 2020 (US 10,548,876), further strengthening Race’s IP position for Zantrene.

The patent further expands Race’s IP portfolio in the therapeutic utility of Zantrene (and related chemical structures), in particular – for methods, formulations and compositions that improve the therapeutic efficacy of Zantrene and reduce side effects.

On October 6, 2021 Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, and a company it founded, Caelum Biosciences, Inc. ("Caelum"), a biotechnology company developing treatments for rare and life-threatening diseases with two ongoing Phase 3 clinical trials, reported the closing of AstraZeneca’s acquisition of Caelum, pursuant to the Development, Option and Stock Purchase Agreement in place between Fortress, Caelum, AstraZeneca’s Alexion and the other parties thereto (as amended, the "DOSPA") (Press release, Caelum Biosciences, OCT 6, 2021, View Source [SID1234590859]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AstraZeneca acquired Caelum for the agreed option exercise price of approximately $150 million. Distributions will be made to all existing Caelum stockholders. The agreement also provides for additional potential payments to Caelum stockholders totaling up to $350 million, payable upon the achievement of regulatory and commercial milestones.

Fortress is eligible to receive approximately 43 percent of all proceeds from the transaction.

On October 6, 2021 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences (Press release, Altimmune, OCT 6, 2021, View Source [SID1234590969]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 5th Annual NASH Investor Conference
Tuesday, October 12, 2021
3:30 pm Eastern Time
H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference
Wednesday, October 13, 2021
4:30 pm Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

On October 6, 2021 LianBio, a Princeton, NJ-Shanghai biopharma, reported that it has filed for a $100 million IPO on the NASDAQ exchange (Press release, LianBio, OCT 6, 2021, View Source [SID1234591005]). LianBio currently has a pipeline of nine in-licensed candidates in five therapeutic areas including oncology. The company was formed by US-based Perceptive Investors to bring promising products from its large portfolio of life science companies to China’s market, while LianBio also in-licenses candidates from other companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!